Neos Therapeutics Announces Positive Phase 3 Study Results For Its Methylphenidate Extended-Release (XR) Oral Disintegrating Tablet (ODT) In ADHD Patients

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GRAND PRAIRIE, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with a portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has completed a positive Phase 3 study for its methylphenidate XR-ODT drug candidate, NT-0102, in children with ADHD.

Help employers find you! Check out all the jobs and post your resume.

Back to news